588-05-6

Basic information

• Product Name: 2-(3-HYDROXYPHENYL)ETHYLAMINE
• Synonyms: 2-(3-HYDROXYPHENYL)ETHYLAMINE;AURORA KA-7836;RARECHEM AN KA 0120;3-Hydroxy-2-phenylethylamine;2-(3-Hydroxyphenyl)ethanamine;3-(2-aminoethyl)phenol;m-Tyramine;3-tyramine
• CAS NO: 588-05-6
• Molecular Formula: C₈H₁₁NO
• Molecular Weight: 137.18
• Product Categories: Amines;Aromatics
• Mol File: 588-05-6.mol
• Article Data: 10

Chemical Properties

• Melting Point: 140 °C
• Boiling Point: 275.5 °C at 760 mmHg
• Flash Point: 120.4 °C
• Appearance: off-white to tan/solid
• Density: 1.103±0.06 g/cm3(Predicted)
• Solubility: H2O: ≥10 mg/mL
• PKA: 9.58±0.10(Predicted)
• CAS DataBase Reference: 2-(3-HYDROXYPHENYL)ETHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-HYDROXYPHENYL)ETHYLAMINE(588-05-6)
• EPA Substance Registry System: 2-(3-HYDROXYPHENYL)ETHYLAMINE(588-05-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• RTECS: SJ5975000
• HazardClass: IRRITANT-HARMFUL
• Hazardous Substances Data: 588-05-6(Hazardous Substances Data)

Usage

Uses

Tyramine is an endogenous compound which exists in the brain as a trace amine but is also an exogenous compound which is found in foods such as cheese and wine.

Synthesis Reference(s)

Journal of Medicinal Chemistry, 27, p. 1321, 1984 DOI: 10.1021/jm00376a017

InChI:InChI=1/C8H11NO/c9-5-4-7-2-1-3-8(10)6-7/h1-3,6,10H,4-5,9H2

Upstream product

• 587-33-7 m-tyrosine 
• 591-31-1 3-methoxy-benzaldehyde 
• 24550-32-1 1-(benzyloxy)-3-(2-nitrovinyl)benzene 
• 100-83-4 meta-hydroxybenzaldehyde 
• 24550-32-1 1-(benzyloxy)-3-[(E)-2-nitroethenyl]benzene 
• 1700-37-4 3-Benzyloxybenzaldehyde 
• 51061-22-4 2-(3-benzyloxyphenyl)ethylamine 
• 53313-95-4 α,3-dihydroxybenzeneacetonitrile 
• 3156-44-3 3-hydroxy-β-nitrostyrene 

Downstream Products

• 173912-96-4 2-<<2-(3-hydroxyphenyl)ethyl>amino>-1,4-naphthoquinone 
• 25200-15-1 6-hydroxy-1-phenyl-1,2,3,4-tetrahydro-isoquinoline 
• 139181-18-3 7-amino-2-(furan-2-yl)-5-[2-(3-hydroxyphenyl)ethyl]amino-[1,2,4]triazolo[1,5-a][1,3,5]triazine 
• 1060788-25-1 (S)-1-(4-methanesulfonamidophenoxy)-3-(3-hydroxyphenylethylamino)-2-propanol 
• 1208104-92-0 C₂₂H₂₀ClNO 
• 1208104-91-9 C₂₂H₂₀N₂O₃ 
• 1208104-93-1 C₂₃H₂₃NO₂ 
• 1194097-46-5 8-chloro-2-({[2-(3-hydroxyphenyl)ethyl]amino}methyl)[1]benzothieno[3,2-d]pyrimidin-4(3H)-one 
• 1292285-99-4 C₁₄H₁₉NO₅ 
• 1292285-61-0 C₁₁H₁₅NO₃ 
• 104083-77-4 4-amino-3-hydroxyphenylethylamine 

Relevant articles and documents

Structure–activity relationship and biological evaluation of berberine derivatives as PCSK9 down-regulating agents

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein and its deficiency markedly enhanced the survival rate of patient with cardiovascular diseases (CVDs). Forty berberine (BBR) derivatives were synthesized and evaluated for their activities on down-regulating the transcription of PCSK9 in HepG2 cells, taking BBR as the lead. Structure–activity relationship (SAR) analysis revealed that 2,3-dimethoxy moiety might be beneficial for activity. Among them, 9k displayed the most potent activity with IC50 value of 9.5 ± 0.5 μM, better than that of BBR. Also, it significantly decreased PCSK9 protein level at cellular level, as well as in the liver and serum of mice in vivo. Furthermore, 9k markedly increased LDLR expression and LDL-C clearance via down-regulating PCSK9 protein. The mechanism of action of 9k is targeting HNF1α and/or Sp1 cluster modulation upstream of PCSK9, a different one from BBR. Therefore, 9k might have the potential to be a novel PCSK9 transcriptional inhibitor for the treatment of atherosclerosis, worthy for further investigation.

SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN

Disclosed herein are small molecule heterocyclic inhibitors of sepiapterin reductase (SPR), and pro-drugs and pharmaceutically acceptable salts thereof. The Also featured are pharmaceutical compositions of the compounds and uses of these compounds for the treatment or prevention of pain (e.g., inflammatory pain, nociceptive pain, functional pain, and neuropathic pain)

PPAR compounds

PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.